zopiclone has been researched along with Chronic Illness in 25 studies
zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007
zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the long-term efficacy of eszopiclone in patients with chronic insomnia." | 9.10 | Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 6.65 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983) |
| "Tolerance or rebound insomnia was not reported." | 6.43 | Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006) |
| "Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer." | 5.37 | Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 5.26 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982) |
| "To determine the long-term efficacy of eszopiclone in patients with chronic insomnia." | 5.10 | Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. ( Amato, DA; Caron, J; Krystal, AD; Laska, E; Roth, T; Walsh, JK; Wessel, TC, 2003) |
| "To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of eszopiclone in the treatment of transient and chronic insomnia in adult and geriatric patients." | 4.82 | Eszopiclone for insomnia. ( Kirkwood, CK; Melton, ST; Wood, JM, 2005) |
| "Insomnia is a common condition in older adults and is associated with a number of adverse medical, social, and psychological consequences." | 2.72 | Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. ( Bjorvatn, B; Havik, OE; Kvale, G; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B, 2006) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 2.65 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1983) |
| "Tolerance or rebound insomnia was not reported." | 2.43 | Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. ( Najib, J, 2006) |
| "In total, 181 chronic insomnia patients were consecutively recruited." | 1.46 | Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months. ( Chen, H; He, J; Liu, Y; Luan, X; Qiu, H; Shen, H; Tu, X; Zhao, K; Zhu, Z, 2017) |
| "Alprazolam is a triazolobenzodiazepine derivative used as a tranquilizer." | 1.37 | Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats. ( Antonescu, A; Bogdan, M; Dobjanschi, L; Moş, I; Mureşan, M; Muţiu, G; Zdrîncă, M, 2011) |
| "Thirty-four participants with chronic primary insomnia." | 1.33 | A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia. ( Bjorvatn, B; Havik, OE; Nielsen, GH; Nordhus, IH; Omvik, S; Pallesen, S; Sivertsen, B; Straume, S, 2006) |
| "6 patients with chronic insomnia, ranging in age from 33 to 57, participated in the study." | 1.26 | Effects of zopiclone on the sleep of chronic insomniacs. ( Mamelak, M; Price, V; Scima, A, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 15 (60.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, K | 1 |
| Luan, X | 1 |
| Liu, Y | 1 |
| Tu, X | 1 |
| Chen, H | 1 |
| Shen, H | 1 |
| Qiu, H | 1 |
| Zhu, Z | 1 |
| He, J | 1 |
| Sivertsen, B | 3 |
| Omvik, S | 3 |
| Pallesen, S | 3 |
| Nordhus, IH | 3 |
| Bjorvatn, B | 3 |
| Mets, MA | 1 |
| Volkerts, ER | 1 |
| Olivier, B | 1 |
| Verster, JC | 1 |
| Zdrîncă, M | 2 |
| Muţiu, G | 1 |
| Bogdan, M | 1 |
| Dobjanschi, L | 1 |
| Antonescu, A | 2 |
| Moş, I | 1 |
| Mureşan, M | 1 |
| Krystal, AD | 1 |
| Walsh, JK | 1 |
| Laska, E | 1 |
| Caron, J | 1 |
| Amato, DA | 1 |
| Wessel, TC | 1 |
| Roth, T | 1 |
| Jacobs, GD | 1 |
| Kramer, M | 1 |
| Vallières, A | 2 |
| Morin, CM | 3 |
| Guay, B | 2 |
| Bastien, CH | 1 |
| LeBlanc, M | 1 |
| Melton, ST | 1 |
| Wood, JM | 1 |
| Kirkwood, CK | 1 |
| Laustsen, G | 1 |
| Najib, J | 1 |
| Havik, OE | 2 |
| Kvale, G | 1 |
| Nielsen, GH | 2 |
| Straume, S | 1 |
| Lesser, GT | 1 |
| Persaud, R | 1 |
| Belleville, G | 1 |
| Mamelak, M | 2 |
| Scima, A | 2 |
| Price, V | 2 |
| Parker, G | 1 |
| Roberts, CJ | 1 |
| Kajimura, N | 1 |
| Kato, M | 1 |
| Okuma, T | 1 |
| Onuma, T | 1 |
| Veĭn, AM | 3 |
| Levin, IaI | 2 |
| Eligulashvili, TS | 2 |
| Posokhov, SI | 2 |
| Kovrov, GV | 2 |
| Bashmakov, MIu | 1 |
| Gasanov, RL | 1 |
| Poluéktov, MG | 1 |
| Fokin, IV | 1 |
| Kolosova, OA | 1 |
| Osipova, VV | 1 |
| Agnoli, A | 1 |
| Manna, V | 1 |
| Martucci, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [NCT00295386] | Phase 4 | 0 participants | Interventional | 2004-01-31 | Completed | ||
| Nightly Light Exposure in Pregnancy: Blue-blocking Glasses as an Intervention to Ease Sleep Disturbances and to Improve Mood[NCT03114072] | 60 participants (Anticipated) | Interventional | 2017-06-06 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
2 reviews available for zopiclone and Chronic Illness
| Article | Year |
|---|---|
Eszopiclone for insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Humans; Hypnotics and Sedatives; ME | 2005 |
Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2006 |
8 trials available for zopiclone and Chronic Illness
| Article | Year |
|---|---|
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Topics: Adult; Aged; Azabicyclo Compounds; Chronic Disease; Circadian Rhythm; Double-Blind Method; Female; H | 2003 |
Sequential treatment for chronic insomnia: a pilot study.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therap | 2004 |
Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study.
Topics: Adult; Azabicyclo Compounds; Behavior Therapy; Chronic Disease; Cognitive Behavioral Therapy; Combin | 2005 |
Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Double-Blind Method; Fema | 2006 |
Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
Topics: Acetamides; Adaptation, Psychological; Adult; Aged; Anxiety; Attitude to Health; Azabicyclo Compound | 2008 |
Effects of zopiclone on the sleep of chronic insomniacs.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Electroencephalography; Fema | 1983 |
[The clinical evaluation of the action of Imovane on patients with insomnia].
Topics: Adolescent; Adult; Analysis of Variance; Azabicyclo Compounds; Chronic Disease; Cluster Analysis; Fe | 1994 |
Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia.
Topics: Adult; Anxiety Disorders; Azabicyclo Compounds; Chronic Disease; Clinical Trials as Topic; Double-Bl | 1989 |
15 other studies available for zopiclone and Chronic Illness
| Article | Year |
|---|---|
Low serum 25-hydroxyvitamin D concentrations in chronic insomnia patients and the association with poor treatment outcome at 2months.
Topics: Adult; Antidepressive Agents; Azabicyclo Compounds; Biomarkers; Case-Control Studies; Chronic Diseas | 2017 |
Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.
Topics: Azabicyclo Compounds; Case-Control Studies; Chronic Disease; Female; Humans; Hypnotics and Sedatives | 2009 |
Effect of hypnotic drugs on body balance and standing steadiness.
Topics: Acetamides; Adult; Aged; Alcohol Drinking; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; D | 2010 |
Effects of Alprazolam, Zolpidem and Zopiclone, and of chronic inflammation on peripheral experimental algesia in Wistar rats.
Topics: Alprazolam; Animals; Azabicyclo Compounds; Chronic Disease; Granuloma, Foreign-Body; Inflammation; M | 2011 |
Is Eszopiclone appropriate and effective for the long-term clinical management of chronic insomnia?
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Long-Term Care; Piperazines; | 2004 |
Hypnotic medication: shed light not heat!
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Hypnotics and Sedatives; Piperazines; Sleep Initiatio | 2004 |
Eszopiclone (lunesta) for treatment of insomnia.
Topics: Azabicyclo Compounds; Chronic Disease; Humans; Metabolic Clearance Rate; Patient Education as Topic; | 2005 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
A comparison of actigraphy and polysomnography in older adults treated for chronic primary insomnia.
Topics: Aged; Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy | 2006 |
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives | 2006 |
Treatment of chronic insomnia with cognitive behavioral therapy vs zopiclone.
Topics: Azabicyclo Compounds; Chronic Disease; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives | 2006 |
Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.
Topics: Adult; Aged; Azabicyclo Compounds; Central Nervous System Depressants; Chronic Disease; Electroencep | 1983 |
Effects of zopiclone on the sleep of chronic insomniacs.
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Electroencephalography; Female; Humans; Hypnotics and | 1982 |
Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics.
Topics: Adult; Anti-Anxiety Agents; Azabicyclo Compounds; Benzodiazepines; Chronic Disease; Humans; Hypnotic | 1994 |
[The effect of Imovane on sleep structure and respiratory indices during sleep in insomnia patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Chronic Disease; Drug Evaluation; | 1997 |
[Clinical and psychological characteristics and therapy of patients with cluster (bunch) headache].
Topics: Adult; Azabicyclo Compounds; Chronic Disease; Cluster Headache; Female; Humans; Hypnotics and Sedati | 2001 |